Gain Therapeutics, Inc. (GANX) intrinsic value & 10-year financials
Gain Therapeutics, Inc. (GANX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.26
- Market cap
- $41.5M
- Revenue (FY2025)
- —
- Revenue growth (7-yr CAGR)
- 24.1%
- ROIC (10-yr avg)
- 1681.7%
- Free cash flow (FY2025)
- —
GANX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$20.2M | -$0.61 | — | — | 887.8% |
| FY2024 | — | -$20.4M | -$0.89 | -$18.9M | — | 4182.2% |
| FY2023 | $55.2K | -$22.3M | -$1.71 | -$18.9M | -40328.3% | -313.6% |
| FY2022 | $132.6K | -$17.6M | -$1.48 | -$14.8M | -13402.5% | -297.8% |
| FY2021 | $133.9K | -$13.9M | -$1.37 | -$12.5M | -10323.6% | 3347.4% |
| FY2020 | $28.9K | -$3.6M | -$1.33 | -$3.3M | -12047.5% | 2284.4% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Gain Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Gain Therapeutics, Inc. has earned high returns on invested capital, averaging 16.8% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Gain Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Gain Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-20.26 per share.